

Edgar Filing: GENEREX BIOTECHNOLOGY CORP - Form 8-K

GENEREX BIOTECHNOLOGY CORP

Form 8-K

July 17, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 15, 2002

Generex Biotechnology Corporation

(Exact name of registrant as specified in its charter)

Delaware ----- (State or other jurisdiction of Incorporation)	000-25169 ----- (Commission File Number)	82-049021 ----- (IRS Employer Identification No.)
--	---	--

33 Harbor Square, Suite 202, Toronto, Ontario Canada M5J 2G2

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code 416/364-2551

(Former name or former address, if changed since last report)

Item 7. Exhibits

- *10.1 Amended and Restated Subscription, Joint Development and Operating Agreement dated January 15, 2002, between Elan Corporation, plc, Elan International Services, Ltd. and Generex Biotechnology Corporation and Generex (Bermuda), Ltd.
- *10.2 Amended and Restated License Agreement dated January 15, 2002, between Elan Corporation, plc and Generex (Bermuda), Ltd.

Edgar Filing: GENEREX BIOTECHNOLOGY CORP - Form 8-K

*10.3 Amended and Restated License Agreement dated January 15, 2002, between Genorex Biotechnology Corporation and Genorex (Bermuda), Ltd.

* Portions of this exhibit have been omitted pursuant to a request for confidential treatment.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENEREX BIOTECHNOLOGY CORPORATION

Dated: July 17, 2003

By: /s/ Rose C. Perri

Rose C. Perri, Chief Operating Officer